Reward 300 Tiger-coinsHi，Tigers：💰
Did you make any money? Share your thoughts!🎯
Catch up fast：These events rocked the markets today.
Tiger Community TOP10 Tickers
🎯 S&P500 Most Active Today 👉@TigerObserver
Weekly Five Key Areas: Macro, Singapore Stocks, Options, Futures, Earnings
Covering five major market segments this week to help you stay ahead of market trends and plan your trades effectively!
✨Tuesday — Singapore Stocks
Singapore stocks opened flat on Tuesday.
CapitaLand Investment (CLI): Bursa-listed CapitaLand Malaysia Trust (CLMT) has agreed to buy five high-specification industrial facilities in the Johor-Singapore Special Economic Zone for RM220.8 million (S$69.2 million), said CLI on Monday. The acquisition supports CLMT’s strategy to expand its industrial and logistics portfolio with high-quality assets in an established location, said the chief executive of CapitaLand Malaysia Reit Management, a wholly owned subsidiary of CLI that manages CLMT. CLI shares closed 0.7 per cent or S$0.02 down at S$2.67, before the news.
Ever Glory United: The Catalist-listed engineering services provider will transfer to the mainboard of the Singapore Exchange on Dec 29, as the proposed move received shareholder approval at the company’s extraordinary general meeting on Monday. The company said on Monday that trading in its shares on the mainboard will commence at 9 am on Dec 29. The counter closed 1.4 per cent or S$0.01 higher at S$0.73, before the news.
📌【Today’s Question】
Christmas trading begins, which stocks are you bullish on?
Join the Topic & Win Tiger Coins! >>
Comments
Oral GLP-1 drugs are expected to capture about 25% of the projected $150 billion obesity market, appealing to patients who prefer pills over injections. Novo Nordisk’s tablet showed strong efficacy, with patients losing an average of 16.6% of body weight in trials, supporting semaglutide’s clinical strength.
For Novo Nordisk, the Wegovy pill offers a critical first-mover advantage amid rising competition. With analysts projecting nearly $2 billion in annual sales by 2030, this approval strengthens NVO’s long-term position in the global obesity market.
@Tiger_comments @TigerStars
I have seen so many people look emaciated and sallow (if I had to guess, this is the problem of the 2 big names of the Wicked movie franchise)
GLP1 can be a good thing especially for the obese and the diabetic, but not controlling it properly is a huge problem. Preying on people's insecurity to make big money is not the way to go.
And seriously, the competition would only heat up, with Eli Lilly making their own jab, Chinese companies producing cheap knockoffs, and the companies in the US that stepped up production when Novo could not keep up with demand.
If we are really looking at Novo to go further, I question their viability for the long term.
凱德置地投資（CLI）：CLI週一表示，在證券交易所上市的凱德置地馬來西亞信託（CLMT）已同意以2.208億令吉（6920萬新元）購買柔佛-新加坡經濟特區的五個高規格工業設施。管理CLMT的CLI全資子公司凱德置地馬來西亞房地產投資信託管理公司首席執行官表示，此次收購支持了CLMT在成熟地點利用優質資產擴大其工業和物流投資組合的戰略。消息傳出前，CLI股價收盤下跌0.7%或0.02新元，至2.67新元。